In the era of big data, based on the deepening of economic globalization and technological globalization, medical globalization is also pressing hard. In addition, the health care system is expanding, and the development of precision medicine is paying more and more attention. The high-profile sequencing market is opening a new round of development on a global scale.

Throughout the global gene sequencing market, the global gene sequencing market has developed rapidly in recent years. From 794 million US dollars in 2007 to 4.5 billion US dollars in 2013, the compound annual growth rate is 33.5%. It is expected to maintain rapid growth in the next few years. It will reach 11.7 billion US dollars in 2018. It is 21.1%.

The corresponding market for genetic sequencing instruments has also exploded. Previously, Illumina accounted for 71% of the global sequencing instrument market; Thermo Fisher took the second place with a 16% market share; Roche ranked third with a market share of 10%. The global market share of the first two sequencer companies is close to 90%, and the genetic sequencer industry has formed an oligopoly.

In the following years, with the continuous upgrading and promotion of the HiSeq series of sequencers, Illumina continued to erode the remaining market share and gradually formed a unique situation. As of 2016, Illumina's market share has grown to 84%.

From the United States to China, nowadays, "precise medicine" has set off a new round of medical revolution from the concept. Under the driving of "technology + capital + policy", the era of universal genetic testing has arrived rapidly. At the same time, the concept of China Medical 's soaring stock market and the market value of more than 100 billion led to the concept of precision medicine was popular with the capital market and received large amounts of financing.

At the same time, the continued blessing of national policies has also provided a solid guarantee for the rapid rise of the genetic sequencing market. In recent years, as the country accelerates the cultivation of the biotechnology industry, grasps the strategic opportunities of China's new science and technology revolution in the new century, and comprehensively builds an innovative country, the bio-industry is booming. In particular, gene sequencing has become a national key area, and it has increased its support. It has successively launched a number of policies and systems to support it, creating a favorable policy environment for the development of the industry.

In March 2015, the Ministry of Science and Technology held a meeting of experts on precision medicine strategy, and planned to write precision medicine into the major scientific and technological plan of the “13th Five-Year Plan”; in June 2015, the “Notice of the National Development and Reform Commission on Implementing Major Engineering Packages for Emerging Industries” In March 2016, the Ministry of Science and Technology issued a special application guide for precision medical research, and China's precision drug and gene sequencing industrialization standards will be established first; in April 2016, the National Development and Reform Commission Genetic Testing Technology Application Demonstration Center Construction Project was launched.

In just a few years, China's genetic sequencing has experienced a series of processes from no supervision, to stop, to pilot declaration, and then to the elimination of pilot restrictions. It is one of the industries with more frequent policy announcements.

Nowadays, with the accelerated development of domestic gene sequencing organizations, genetic testing companies led by Huada Gene are rapidly emerging. As far as the Chinese market is concerned, on the basis of domestic leading, the capital market and policies are favorable, and the gene sequencing enterprises will continue to stand firm in the first echelon of the genetic sequencing industry, providing an endless source of power for China's precision medicine industry to lead the world. At the same time, with the continuous breakthrough of technology, gene technology will be widely used in research fields such as complex diseases, agricultural genomics, microbiology and metagenomics, which will bring about tremendous changes in human health, agriculture and environmental protection.

In Heavy Syrup

Yellow Clingstone Peaches, peeled, pitted, Yellow Peahc Halves, slices and dices, In Heavy Syrup.

Fomdas control product quality and safety from raw material origins by planting fresh Ams Peaches. About 1/3 of fresh Yellow Cling Peach are picked from Fomdas own orchards, and the rest 2/3 are purchased qualified suppliers. We have strict and complete qualified supplier assessment system for new supplier assessment. Every piece of fresh raw material are pesticides and heavy metal residual tested before putting into production of Canned Peaches In Heavy Syrup. Moreover, all peaches are selected on appearance, color and maturity, they are processed at the peak of freshness.

Fomdas Peaches In Heavy Syrup is natural and healthy, they are gluten free and Non-GMO. It's a good source of Vitamin C, a perfect snack for both kids and adults.

Fomdas Sliced Peahces In Heavy Syrup is shelf-stable, with it, you can enjoy good taste of fresh peaches anywhere and anytime.

Peaches In Heavy Syrup, Yellow Peach Halves, Sliced Peaches In Heavy Syrup, Canned Peaches In Heavy Syrup, Yellow Clingstone Peaches

ZHEJIANG FOMDAS FOODS CO., LTD. , https://www.fomdasfoods.com